Vesnarinone and amrinone reduce the systemic inflammatory response syndrome Koh Takeuchi, MD, Pedro J. del Nido, MD, Andra E. Ibrahim, MD, Hung Cao-Danh, PhD, Ingeborg Friehs, MD, Paul Glynn, PhD, Dimitrios Poutias, BS, Douglas B. Cowan, PhD, Francis X. McGowan, MD The Journal of Thoracic and Cardiovascular Surgery Volume 117, Issue 2, Pages 375-382 (February 1999) DOI: 10.1016/S0022-5223(99)70436-8 Copyright © 1999 Mosby, Inc. Terms and Conditions
Fig. 1 Cytokine production in response to endotoxin. Data are mean ± SD; n = 8 each. A, Plasma TNF-α in animals treated with lipopolysaccharide (LPS) alone, lipopolysaccharide + vesnarinone (VES), or lipopolysaccharide + amrinone (AMR). B, Plasma IL-1β concentrations. Both vesnarinone and amrinone significantly suppressed lipopolysaccharide-stimulated TNF and IL-1 production compared with lipopolysaccharide alone (analysis of variance/Bonferroni). The Journal of Thoracic and Cardiovascular Surgery 1999 117, 375-382DOI: (10.1016/S0022-5223(99)70436-8) Copyright © 1999 Mosby, Inc. Terms and Conditions
Fig. 2 Lung myeloperoxidase activity was reduced by vesnarinone (VES) treatment (P = .03) compared with either lipopolysaccharide (LPS) alone or lipopolysaccharide + amrinone (AMR). Data are mean ± SD; n = 4 each. The Journal of Thoracic and Cardiovascular Surgery 1999 117, 375-382DOI: (10.1016/S0022-5223(99)70436-8) Copyright © 1999 Mosby, Inc. Terms and Conditions
Fig. 3 Calcium-independent nitric oxide synthase activity in myocardial extracts from animals treated with lipopolysaccharide (LPS) alone, lipopolysaccharide + vesnarinone (VES), or lipopolysaccharide + amrinone (AMR). Data are mean ± SD; n = 6 each. Both vesnarinone and amrinone reduced iNOS activity resulting from lipopolysaccharide treatment (analysis of variance/Bonferroni, P = .04). The Journal of Thoracic and Cardiovascular Surgery 1999 117, 375-382DOI: (10.1016/S0022-5223(99)70436-8) Copyright © 1999 Mosby, Inc. Terms and Conditions